Affinity Asset Advisors, LLC Ventyx Biosciences, Inc. Transaction History

Affinity Asset Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$28.53 - $39.55 $4.55 Million - $6.3 Million	-159,312 Reduced 61.27%	100,696 $3.3 Million
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $572,051 - $904,310	19,385 Added 8.06%	260,008 $8.71 Million
Q4 2022 Feb 13, 2023	BUY	$24.16 - $36.38 $1.71 Million - $2.57 Million	70,623 Added 41.54%	240,623 $7.89 Million
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $2.15 Million - $6.58 Million	170,000 New	170,000 $5.94 Million

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $135M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.